Skip to main
STOK

STOK Stock Forecast & Price Target

STOK Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 22%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Stoke Therapeutics Inc. has demonstrated a strong financial performance in FY25, with revenues increasing significantly to $184 million, primarily driven by a $165 million upfront payment from a collaboration agreement with Biogen. The company is actively advancing its lead candidate, zorevunersen, showing promising results in its phase I/II studies with substantial seizure reductions in Dravet syndrome patients, which bodes well for its ongoing phase III EMPEROR study. Furthermore, the investment in research and development, reflected by a 55% increase in R&D expenses to $138 million, underscores Stoke's commitment to advancing its innovative RNA medicines targeting haploinsufficiency diseases.

Bears say

The financial outlook for Stoke Therapeutics Inc. is concerning due to significant risks surrounding its intellectual property, notably the potential for key patents to be disputed or not issued, which could hinder market success and negatively impact valuation. The company reported a net loss of $6.9 million for 2025, with an earnings per share of -$0.12, indicating ongoing financial challenges and a lack of profitability anticipated for several years. Additionally, the necessity for raising further capital poses financial risks, as any equity financing could lead to share dilution, further impairing shareholder value.

STOK has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 22% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Stoke Therapeutics Inc (STOK) Forecast

Analysts have given STOK a Strong Buy based on their latest research and market trends.

According to 9 analysts, STOK has a Strong Buy consensus rating as of Apr 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Stoke Therapeutics Inc (STOK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.